BRPI0412404A - uso de rapamicina e de derivado da rapamicina para o tratamento da perda óssea - Google Patents
uso de rapamicina e de derivado da rapamicina para o tratamento da perda ósseaInfo
- Publication number
- BRPI0412404A BRPI0412404A BRPI0412404-9A BRPI0412404A BRPI0412404A BR PI0412404 A BRPI0412404 A BR PI0412404A BR PI0412404 A BRPI0412404 A BR PI0412404A BR PI0412404 A BRPI0412404 A BR PI0412404A
- Authority
- BR
- Brazil
- Prior art keywords
- rapamycin
- treatment
- bone loss
- derivative
- rapamycin derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"USO DA RAPAMICINA E DE DERIVADO DA RAPAMICINA PARA O TRATAMENTO DA PERDA óSSEA". A presente invenção refere-se a um novo uso da rapamicina e de derivados da rapamicina.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0315965A GB0315965D0 (en) | 2003-07-08 | 2003-07-08 | Organic compounds |
GB0315963A GB0315963D0 (en) | 2003-07-08 | 2003-07-08 | Organic compounds |
PCT/EP2004/007437 WO2005005434A1 (en) | 2003-07-08 | 2004-07-07 | Use of rapamycin and rapamycin derivatives for the treatment of bone loss |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0412404A true BRPI0412404A (pt) | 2006-09-05 |
Family
ID=34066609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0412404-9A BRPI0412404A (pt) | 2003-07-08 | 2004-07-07 | uso de rapamicina e de derivado da rapamicina para o tratamento da perda óssea |
Country Status (13)
Country | Link |
---|---|
US (3) | US20060173033A1 (pt) |
EP (1) | EP1646634B1 (pt) |
JP (1) | JP4755981B2 (pt) |
AT (1) | ATE414089T1 (pt) |
AU (1) | AU2004255340B2 (pt) |
BR (1) | BRPI0412404A (pt) |
CA (1) | CA2531454C (pt) |
DE (1) | DE602004017736D1 (pt) |
ES (1) | ES2316995T3 (pt) |
MX (1) | MXPA06000117A (pt) |
PL (1) | PL1646634T3 (pt) |
PT (1) | PT1646634E (pt) |
WO (1) | WO2005005434A1 (pt) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2377847T3 (es) | 1999-01-13 | 2012-04-02 | Bayer Healthcare Llc | Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38 |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
MXPA04007832A (es) | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aril-ureas con actividad inhibitoria de angiogenesis. |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
DE602004007382T2 (de) | 2003-05-20 | 2008-04-17 | Bayer Pharmaceuticals Corp., West Haven | Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten |
CN1856469B (zh) | 2003-07-23 | 2013-03-06 | 拜耳医药保健有限责任公司 | 用于治疗和预防疾病和疾病症状的氟代ω-羧芳基二苯基脲 |
SI1983984T1 (en) * | 2006-02-02 | 2018-06-29 | Novartis Ag | Treatment of tuberous sclerosis |
WO2008022256A2 (en) * | 2006-08-16 | 2008-02-21 | Blagosklonny Mikhail V | Methods and compositions for preventing or treating age-related diseases |
KR100937456B1 (ko) | 2007-08-01 | 2010-01-19 | 한국생명공학연구원 | 인간배아줄기세포를 조골세포 직계열로 분화시키는 방법 |
EP2416792A4 (en) | 2009-04-10 | 2012-10-24 | Haiyan Qi | NEW ANTI-AGING APPROACHES AND METHOD FOR IDENTIFYING THEM |
WO2013043529A1 (en) | 2011-09-19 | 2013-03-28 | Emory University | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto |
LT2782584T (lt) | 2011-11-23 | 2021-09-10 | Therapeuticsmd, Inc. | Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
PL2974728T3 (pl) | 2013-03-13 | 2020-10-19 | Santen Pharmaceutical Co., Ltd | Środek terapeutyczny na dysfunkcję gruczołu Meiboma |
AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
JP6709493B2 (ja) | 2015-01-26 | 2020-06-17 | 国立大学法人京都大学 | 進行性骨化性線維異形成症治療剤 |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
WO2017055370A1 (en) * | 2015-09-28 | 2017-04-06 | Fondazione Telethon | Treatment of bone growth disorders |
US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
PL3558955T3 (pl) | 2016-12-22 | 2021-12-27 | Amgen Inc. | Pochodne benzoizotiazolu, izotiazolo[3,4-b]pirydyny, chinazoliny, ftalazyny, pirydo[2,3-d]pirydazyny i pirydo[2,3-d]pirymidyny jako inhibitory kras g12c do leczenia raka płuc, trzustki lub jelita grubego |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
MA50077A (fr) | 2017-09-08 | 2020-07-15 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
JP7361722B2 (ja) | 2018-05-04 | 2023-10-16 | アムジエン・インコーポレーテツド | Kras g12c阻害剤及び同一物の使用方法 |
JP7266043B2 (ja) | 2018-05-04 | 2023-04-27 | アムジエン・インコーポレーテツド | KRas G12C阻害剤及びそれを使用する方法 |
US10988485B2 (en) | 2018-05-10 | 2021-04-27 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
MA52765A (fr) | 2018-06-01 | 2021-04-14 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
JP7357644B2 (ja) | 2018-06-11 | 2023-10-06 | アムジエン・インコーポレーテツド | がんを処置するためのkras g12c阻害剤 |
EP3807276A2 (en) | 2018-06-12 | 2021-04-21 | Amgen Inc. | Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer |
HUE067446T2 (hu) | 2018-06-15 | 2024-10-28 | Janssen Pharmaceutica Nv | Rapamicin analógok és alkalmazásaik |
JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
JP7454572B2 (ja) | 2018-11-19 | 2024-03-22 | アムジエン・インコーポレーテツド | Kras g12c阻害剤及びその使用方法 |
EP3898616B1 (en) | 2018-12-20 | 2024-10-02 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
AU2019401495A1 (en) | 2018-12-20 | 2021-06-24 | Amgen Inc. | Heteroaryl amides useful as KIF18A inhibitors |
US20220073504A1 (en) | 2018-12-20 | 2022-03-10 | Amgen Inc. | Kif18a inhibitors |
AR117490A1 (es) | 2018-12-20 | 2021-08-11 | Amgen Inc | Inhibidores de kif18a |
CA3130083A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
AU2020232242A1 (en) | 2019-03-01 | 2021-09-09 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
CR20210665A (es) | 2019-05-21 | 2022-01-25 | Amgen Inc | Formas en estado sólido |
MX2022001296A (es) | 2019-08-02 | 2022-02-22 | Amgen Inc | Inhibidores de kif18a. |
CN114302880A (zh) | 2019-08-02 | 2022-04-08 | 美国安进公司 | Kif18a抑制剂 |
WO2021026101A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
AU2020325115A1 (en) | 2019-08-02 | 2022-03-17 | Amgen Inc. | Pyridine derivatives as KIF18A inhibitors |
WO2021055728A1 (en) | 2019-09-18 | 2021-03-25 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
MX2022004656A (es) | 2019-10-24 | 2022-05-25 | Amgen Inc | Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer. |
IL292438A (en) | 2019-10-28 | 2022-06-01 | Merck Sharp & Dohme | Small molecules that inhibit the g12c mutant of kras |
WO2021085653A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
US11739074B2 (en) | 2019-11-04 | 2023-08-29 | Revolution Medicines, Inc. | Ras inhibitors |
AU2020379734A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
CR20220243A (es) | 2019-11-04 | 2022-08-04 | Revolution Medicines Inc | Inhibidores de ras |
TW202128688A (zh) | 2019-11-08 | 2021-08-01 | 美商銳新醫藥公司 | 雙環雜芳基化合物及其用途 |
JP2023501528A (ja) | 2019-11-14 | 2023-01-18 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の改善された合成 |
CA3161156A1 (en) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
CN114980976A (zh) | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
EP4069223A4 (en) * | 2019-12-05 | 2023-12-20 | Janssen Pharmaceutica NV | RAPAMYCIN ANALOGS AND THEIR USES |
CN114929279A (zh) | 2020-01-07 | 2022-08-19 | 锐新医药公司 | Shp2抑制剂给药和治疗癌症的方法 |
WO2021215544A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
WO2021215545A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c |
KR20230031926A (ko) | 2020-07-15 | 2023-03-07 | 다이호야쿠힌고교 가부시키가이샤 | 종양의 치료에 사용되는 피리미딘 화합물을 포함하는 조합 |
MX2023002248A (es) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. |
PE20231207A1 (es) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer |
TW202241885A (zh) | 2020-12-22 | 2022-11-01 | 大陸商上海齊魯銳格醫藥研發有限公司 | Sos1抑制劑及其用途 |
WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
CN117500811A (zh) | 2021-05-05 | 2024-02-02 | 锐新医药公司 | 共价ras抑制剂及其用途 |
TW202309052A (zh) | 2021-05-05 | 2023-03-01 | 美商銳新醫藥公司 | Ras抑制劑 |
US20240317759A1 (en) | 2021-05-28 | 2024-09-26 | Taiho Pharmaceutical Co., Ltd. | Small molecule inhibitors of kras mutated proteins |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
TW202340214A (zh) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | 做為shp2抑制劑之吡唑并吡𠯤化合物 |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
WO2024216016A1 (en) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
WO2024216048A1 (en) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
CN117223676B (zh) * | 2023-09-25 | 2024-08-20 | 武汉大学 | 面中部发育畸形动物选育方法、辅助选育试剂和预防药物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5258389A (en) * | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
US5527907A (en) * | 1993-11-19 | 1996-06-18 | Abbott Laboratories | Macrolide immunomodulators |
US20030129215A1 (en) * | 1998-09-24 | 2003-07-10 | T-Ram, Inc. | Medical devices containing rapamycin analogs |
WO2001044257A1 (en) * | 1999-12-17 | 2001-06-21 | Ariad Pharmaceuticals, Inc. | Proton pump inhibitors |
KR101004224B1 (ko) * | 2002-02-01 | 2010-12-27 | 어리어드 파마슈티칼스, 인코포레이티드 | 인 함유 화합물 및 이의 용도 |
-
2004
- 2004-07-07 PT PT04740750T patent/PT1646634E/pt unknown
- 2004-07-07 AT AT04740750T patent/ATE414089T1/de active
- 2004-07-07 AU AU2004255340A patent/AU2004255340B2/en not_active Ceased
- 2004-07-07 PL PL04740750T patent/PL1646634T3/pl unknown
- 2004-07-07 CA CA2531454A patent/CA2531454C/en not_active Expired - Fee Related
- 2004-07-07 JP JP2006518133A patent/JP4755981B2/ja not_active Expired - Fee Related
- 2004-07-07 US US10/563,707 patent/US20060173033A1/en not_active Abandoned
- 2004-07-07 MX MXPA06000117A patent/MXPA06000117A/es active IP Right Grant
- 2004-07-07 ES ES04740750T patent/ES2316995T3/es not_active Expired - Lifetime
- 2004-07-07 WO PCT/EP2004/007437 patent/WO2005005434A1/en active Search and Examination
- 2004-07-07 BR BRPI0412404-9A patent/BRPI0412404A/pt not_active IP Right Cessation
- 2004-07-07 EP EP04740750A patent/EP1646634B1/en not_active Expired - Lifetime
- 2004-07-07 DE DE602004017736T patent/DE602004017736D1/de not_active Expired - Lifetime
-
2009
- 2009-03-05 US US12/398,225 patent/US20090221503A1/en not_active Abandoned
-
2012
- 2012-05-18 US US13/475,044 patent/US20120232011A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2316995T3 (es) | 2009-04-16 |
MXPA06000117A (es) | 2006-04-27 |
JP2009513522A (ja) | 2009-04-02 |
ATE414089T1 (de) | 2008-11-15 |
CA2531454C (en) | 2011-10-25 |
US20090221503A1 (en) | 2009-09-03 |
CA2531454A1 (en) | 2005-01-20 |
PL1646634T3 (pl) | 2009-04-30 |
US20060173033A1 (en) | 2006-08-03 |
EP1646634B1 (en) | 2008-11-12 |
DE602004017736D1 (de) | 2008-12-24 |
AU2004255340A1 (en) | 2005-01-20 |
WO2005005434A1 (en) | 2005-01-20 |
US20120232011A1 (en) | 2012-09-13 |
PT1646634E (pt) | 2009-02-16 |
EP1646634A1 (en) | 2006-04-19 |
AU2004255340B2 (en) | 2008-05-01 |
JP4755981B2 (ja) | 2011-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0412404A (pt) | uso de rapamicina e de derivado da rapamicina para o tratamento da perda óssea | |
LTPA2020503I1 (lt) | Rapamicino darinys, skirtas kasos vėžio gydymui | |
MXPA06000123A (es) | Suspension aislante de apoyo central de resorte rapido de plastico y metodo para fabricar y ensamblar el mismo. | |
ECSP034750A (es) | Derivados de espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa-7 | |
ECSP045081A (es) | Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados | |
DK1478629T3 (da) | N-aryl-2-oxazolidinon-5-carboxamider og deres derivater og deres anvendelse som antibakterielle midler | |
CY2017048I1 (el) | Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης | |
ECSP066467A (es) | Formas Polimórficas de 3-(4-amino-1-Oxo-1-3 DIhidroisoindol-2-IL)-Piperidin-2,6-Diona | |
PT1147083E (pt) | Derivados de arilpiperazinil-ciclohexilindole para o tratamento da depressao | |
NO20050426L (no) | Arylkarbonylderivater som terapeutiske midler | |
ATE501135T1 (de) | Piperidinamino-benzimidazol-derivate al respiratorisches syncytialvirus replikation inhibitoren | |
BRPI0607198A2 (pt) | composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica | |
PT1282616E (pt) | Derivados de hidroxifenil-piperidin-4-ilideno-metil-benzamida para o tratamentoda dor | |
NO20050665L (no) | Pyrrolidonderivater som MAOE inhibitoere | |
UY29213A1 (es) | Derivados de quinolina e isoquinolina 5-sustitiuidos, un procedimiento para su preparación y su uso como inhibidores de la inflamación | |
CL2004001678A1 (es) | Compuestos derivados de oxazolidinona; composicion farmaceutica; y uso de los compuestos como agentes bacterianos. | |
NO20043952L (no) | Benzofuran- og benzotiofenderivater som er nyttige ved behandling av hyperproliferative forstyrrelser | |
CO5660287A2 (es) | Derivados de tetrahidrocarbazol y su uso farmaceutico | |
UY28344A1 (es) | Nuevos compuestos | |
BRPI0415390A (pt) | compostos de pirazinona substituìda para o tratamento da inflamação | |
ITRM20030355A1 (it) | Composti ad attivita' citotossica derivati della combretastatina. | |
PT1286986E (pt) | Derivados de quinolil-piperidin-4-ilideno-metil-benzamida para o tratamento da dor | |
CR8135A (es) | Triazolopirimidinas | |
SV2006002220A (es) | Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios ref. p-sv-78.836/cd | |
PT1282599E (pt) | Derivados dissulfureto uteis para tratar doencas alergicas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |